CancerDrs Find care

Brain Cancer clinical trials in Missouri

25 actively recruiting brain cancer trials at 19 sites across Missouri.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Missouri:
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • MU Health - University Hospital/Ellis Fischel Cancer Center — Columbia, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
  • Parkland Health Center - Farmington — Farmington, Missouri
  • Mercy Hospital Springfield — Springfield, Missouri
Phase 3 Recruiting Academic/Other

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…

Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in Missouri:
  • Saint Francis Medical Center — Cape Girardeau, Missouri
  • Parkland Health Center - Farmington — Farmington, Missouri
  • Freeman Health System — Joplin, Missouri
  • Sainte Genevieve County Memorial Hospital — Sainte Genevieve, Missouri
  • Mercy Hospital Springfield — Springfield, Missouri
Phase 3 Recruiting NIH

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Missouri:
  • Children's Mercy Hospitals and Clinics — Kansas City, Missouri
  • Cardinal Glennon Children's Medical Center — St Louis, Missouri
  • Washington University School of Medicine — St Louis, Missouri
Phase 3 Recruiting Industry

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Missouri:
  • Washington University School of Medicine/St. Louis Children's Hospital — St Louis, Missouri
Phase 2, Phase 3 Recruiting Academic/Other

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …

Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Missouri:
  • Washington University School of Medicine - Siteman Cancer Center — St Louis, Missouri
Phase 3 Recruiting Industry

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade g…

Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT05566795
Sites in Missouri:
  • St. Louis Children's Hospital — St Louis, Missouri
Phase 3 Recruiting Industry

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…

Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in Missouri:
  • Washington University — St Louis, Missouri
Phase 2 Recruiting Network

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Missouri:
  • Saint Louis Cancer and Breast Institute-Ballwin — Ballwin, Missouri
  • Central Care Cancer Center - Bolivar — Bolivar, Missouri
  • Cox Cancer Center Branson — Branson, Missouri
  • Saint Francis Medical Center — Cape Girardeau, Missouri
  • Southeast Cancer Center — Cape Girardeau, Missouri
Phase 1, Phase 2 Recruiting NIH

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Missouri:
  • Children's Mercy Hospitals and Clinics — Kansas City, Missouri
  • Cardinal Glennon Children's Medical Center — St Louis, Missouri
  • Washington University School of Medicine — St Louis, Missouri
  • Mercy Hospital Saint Louis — St Louis, Missouri
Phase 1, Phase 2 Recruiting Network

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…

Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Missouri:
  • Children's Mercy Hospitals and Clinics — Kansas City, Missouri
  • Washington University School of Medicine — St Louis, Missouri
Phase 2 Recruiting NIH

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05859334
Sites in Missouri:
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
  • Washington University School of Medicine — St Louis, Missouri
  • Siteman Cancer Center-South County — St Louis, Missouri
  • Siteman Cancer Center at Christian Hospital — St Louis, Missouri
Phase 2 Recruiting Academic/Other

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.

Sponsor: Giselle Sholler
NCT ID: NCT04696029
Sites in Missouri:
  • Children's Mercy Hospitals and Clinics — Kansas City, Missouri
  • Cardinal Glennon Children's Medical Center — St Louis, Missouri
Phase 2 Recruiting Academic/Other

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIP…

Sponsor: Nationwide Children's Hospital
NCT ID: NCT05096481
Sites in Missouri:
  • St. Louis Children's Hospital — St Louis, Missouri
Phase 2 Recruiting Academic/Other

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called ki…

Sponsor: University of California, San Francisco
NCT ID: NCT07110246
Sites in Missouri:
  • St. Louis Children's Hospital Washington University in St. Louis — St Louis, Missouri
Phase 1 Recruiting Industry

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Missouri:
  • Saint Luke's Cancer Institute — Kansas City, Missouri
  • Washington University School of Medicine — St Louis, Missouri
Phase 1 Recruiting Network

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or…

Sponsor: Children's Oncology Group
NCT ID: NCT06894979
Sites in Missouri:
  • Washington University School of Medicine — St Louis, Missouri
Phase 1 Recruiting Academic/Other

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

This phase I trial studies the side effects of nivolumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive). Immunotherap…

Sponsor: Sabine Mueller, MD, PhD
NCT ID: NCT04323046
Sites in Missouri:
  • Washington University St. Louis — St Louis, Missouri
EARLY Phase 1 Recruiting Academic/Other

Window of Opportunity Study of DSP-0390 in Gliomas

This study focuses on determining the pharmacokinetic and pharmacodynamic effect of DSP-0390 in brain and blood from patients with IDH-mutant WHO grade II or III glioma undergoing tumor resection. Tissue will be collected during surgical r…

Sponsor: Washington University School of Medicine
NCT ID: NCT06636162
Sites in Missouri:
  • Washington University School of Medicine — St Louis, Missouri
Phase 1 Recruiting Academic/Other

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

This is a pilot phase Ib study of the safety of dapagliflozin (in addition to standard of care treatment) for the treatment of pediatric patients with recurrent brain tumors and relapsed/refractory solid tumors. The primary hypothesis is t…

Sponsor: Washington University School of Medicine
NCT ID: NCT05521984
Sites in Missouri:
  • Washington University School of Medicine/St. Louis Children's Hospital — St Louis, Missouri
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Missouri:
  • Massive Bio SYNERGY-AI site — Kansas City, Missouri
  • Massive Bio SYNERGY-AI site — St Louis, Missouri
NA Recruiting Industry

REMASTer: REcurrent Brain Metastases After SRS Trial

Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS…

Sponsor: Monteris Medical
NCT ID: NCT05124912
Sites in Missouri:
  • WashU — St Louis, Missouri
NA Recruiting Academic/Other

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in the pilot phase of performing real-time drug screening on tissue taken during su…

Sponsor: University of California, San Francisco
NCT ID: NCT05057702
Sites in Missouri:
  • St. Louis Children's Hospital / Washington University in St. Louis — St Louis, Missouri
NA Recruiting Academic/Other

Cognitive Biomarkers in Pediatric Brain Tumor Patients

The investigators will focus on three cohorts of brain tumor patients aged, 4-18 years, to answer two critical questions: 1) Can the investigators acquire high quality data relevant to cognitive function during the peri-diagnostic period a…

Sponsor: Washington University School of Medicine
NCT ID: NCT02914067
Sites in Missouri:
  • Washington University School of Medicine — St Louis, Missouri
NA Recruiting Academic/Other

Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

This clinical study to evaluate sonobiopsy is significant because sonobiopsy will fundamentally enhance the clinician's insight into the molecular features of an intracranial lesion to tailor treatment approaches and optimize outcomes. In …

Sponsor: Washington University School of Medicine
NCT ID: NCT05281731
Sites in Missouri:
  • Washington University School of Medicine — St Louis, Missouri
Recruiting Academic/Other

Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients

With modern therapy, the survival rate for pediatric brain tumor patients has significantly improved, with over 70% of patients surviving their disease. However, this progress often comes at the cost of substantial morbidity, with cognitiv…

Sponsor: Washington University School of Medicine
NCT ID: NCT06185686
Sites in Missouri:
  • Washington University School of Medicine/Saint Louis Children's Hospital — St Louis, Missouri

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20